Last reviewed · How we verify
AZD5363when combined with weekly paclitaxel.
ATR kinase inhibitor
ATR kinase inhibitor Used for Triple-negative breast cancer.
At a glance
| Generic name | AZD5363when combined with weekly paclitaxel. |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | ATR kinase inhibitor |
| Target | ATR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AZD5363 is a potent and selective inhibitor of the ataxia-telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway.
Approved indications
- Triple-negative breast cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: